NCT02576054View on ClinicalTrials.gov

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

August 8, 2018

Study Completion Date

August 8, 2018

Conditions
Anogenital Human Papilloma Virus InfectionCondyloma Acuminata
Interventions
BIOLOGICAL

V501

Quadrivalent HPV \[Type 6, 11, 16 and 18\] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

Trial Locations (1)

102-8667

MSD K.K., Chiyoda-Ku, Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02576054 - Safety and Tolerability Study of V501 in Japanese Boys (V501-200) | Biotech Hunter | Biotech Hunter